1. Analyst View

2. Clinical Trials Market Overview
2.1 Global Clinical Research Market
2.2 Clinical Research Market in Asia-Pacific
2.3 Clinical Research Market in India
2.3.1 Number of Clinical Trials
2.3.2 Clinical Trials by Type
2.3.3 Clinical Research Market
2.3.4 Patient Participation
2.3.5 Market Trends

3. Size and Patient Pool Availability
3.1 Population and Demographics
3.2 Disease Profile
3.3 Patient Availability and Recruitment

4. Infrastructure and Expertise
4.1 Education
4.2 Clinical Research Professionals
4.3 Hospital Beds
4.4 ICH/GCP Compliant Sites

5. Cost Analysis
5.1 Phase I Clinical Trials
5.1.1 Cost of Staff
5.1.2 Cost of Utility
5.2 Phase II Clinical Trials
5.2.1 Cost of Infrastructure and Staff
5.2.2 Cost of Utility
5.3 Phase III Clinical Trials
5.3.1 Cost of Infrastructure and Staff
5.3.2 Cost of Utility
5.4 Phase IV Clinical Trials
5.4.1 Cost of Infrastructure and Staff
5.4.2 Cost of Utility

6. Success and Risk Factor Analysis
6.1 Lower Cost
6.2 Faster Completion
6.3 Pathology and Diagnostic Market
6.4 Clinical Data Management
6.5 Increasing Competition between Developing Countries
6.6 Demand-Supply Gap of Clinical Professionals
6.7 Long Time for Approval

7. Regulatory Environment
7.1 The Institutional Ethics Committee (IEC)
7.2 Trials that can/cannot be Conducted in India
7.3 Clinical Trials Registry
7.4 Intellectual Property Protection
7.5 Incentives Given by the Government

8. RNCOS Recommendations

9. Key Players
9.1 Syngene International Ltd
9.2 Quintiles Research (India) Private Limited
9.3 Lambda Therapeutic Research Ltd
9.4 Bioserve Clinical Research Pvt. Ltd.
9.5 Veeda Clinical Research
9.6 IGATE Clinical Research International
9.7 PharmaNet
9.8 Vimta Labs

List of Figures:

Figure 2-1: Global - Number of Clinical Trials (2007-2009)
Figure 2-2: Global - Clinical Research Market (Billion US$), 2007-2009
Figure 2-3: Global - Forecast for Clinical Research Market (Billion US$), 2010-2012
Figure 2-4: Global - Clinical Research Market by Phase (%), 2008
Figure 2-5: Asia-Pacific - Share of Countries in Clinical Trial Studies (2008)
Figure 2-6: Number of Clinical Trials (2007-2009)
Figure 2-7: Forecast for Number of Clinical Trials (2010-2012)
Figure 2-8: Clinical Trials by Phase (%)
Figure 2-9: Clinical Trials by Therapy (%)
Figure 2-10: Clinical Research Market (Million US$), 2007-2009
Figure 2-11: Forecast for Clinical Research Market (Million US$), 2010-2012
Figure 2-12: Forecast for Number of Patients Participating in Clinical Trials (Million), 2010-2012
Figure 2-13: Pharma Outsourcing Market (Billion US$), 2007-2009
Figure 2-14: Pharma Outsourcing Market by Segment (%), 2008
Figure 3-1: Population (Million), 2006-2009
Figure 3-2: Forecast for Population (Million), 2010-2012
Figure 3-3: Population Breakup by Age Group (%), 2006-2009
Figure 3-4: Forecast for Population Breakup by Age Group (%), 2010-2012
Figure 3-5: Various Causes of Death (%), 2008
Figure 3-6: Forecast for Various Causes of Death (%), 2030
Figure 3-7: New and Total Number of Cancer Patients (‘000)
Figure 3-8: Number of Hypertension Patients (Million), 2000, 2007 & 2025
Figure 3-9: Number of Coronary Heart Patients (Million), 2005 & 2015
Figure 3-10: Recruitment Time for Patients Participating in Clinical Trials in Comparison to US (Days)
Figure 3-11: Number of Patient per Site in Comparison to US
Figure 4-1: Number of Individuals with Bachelor and Higher Degree (Million), 1991, 2004, 2006 & 2008
Figure 4-2: Number of Graduates and Postgraduates (Million), 2004
Figure 4-3: Share of Science Doctorates in Total Doctorates (2004)
Figure 4-4: Number of Doctors in Comparison to US and Germany (‘000), 2008
Figure 4-5: Number of Doctors (‘000), 2007-2009
Figure 4-6: Forecast for Number of Doctors (‘000), 2010-2012
Figure 4-7: Number of GCP Trained Investigators (2002 & 2005)
Figure 4-8: Number of GCP Trained Investigators in Comparison to US
Figure 4-9: Number of Hospital Beds (‘000), 2007-2009
Figure 4-10: Number of Hospital Beds in Comparison to UK, US and Germany (‘000), 2008
Figure 4-11: Forecast for Number of Hospital Beds (‘000), 2010-2012
Figure 4-12: Number of Sites for Clinical Trials in Comparison to UK, US and Germany
Figure 5-1: Average Cost per Patient for Conducting Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-2: Average Cost per Patient for Conducting Phase I Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-3: Average Cost per Patient for Conducting Phase II Clinical Trials in comparison to UK, US and Germany (US$)
Figure 5-4: Annual Cost of Office Space for Conducting Phase II Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-5: Average Cost per Patient for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-6: Annual Cost of Office Space for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-7: Average Cost per Patient for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-8: Annual Cost of Office Space for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 6-1: Average Cost for Conducting Various Clinical Trial Phases in Comparison to US
Figure 6-2: Time Taken for Conducting Clinical Trials by Phase in Comparison to US (Months)
Figure 6-3: Numbers of Clinical Trials Completed on Time in Comparison to UK, US and Germany
Figure 6-4: IVD Market (Million US$), 2008 & 2012
Figure 6-5: Average Time for Approval of Clinical Trials in Comparison to UK, US and Germany (Weeks)
Figure 9-1: Share of Players in Bio-services Market (2008)

List of Tables:

Table 3-1: Number of Deaths due to Various Causes (2005)
Table 3-2: Number of Diabetic Patients in Age Group 20-79 (‘000), 2007
Table 3-3: Forecast for Number of Diabetic Patients in Age Group 20-79 (‘000), 2025
Table 3-4: New Cancers Incidences (per ‘00,000 Females), 2005
Table 3-5: New Cancers Incidences (per ‘00,000 Males), 2005
Table 3-6: Prevalence of Overweight & Obesity in Males and Females (%), 2005 & 2015
Table 4-1: Structure of Medical Education
Table 4-2: Number of GLA Approved Facilities by Type
Table 5-1: Annual Cost of Staff for Conducting Phase I Clinical Trials in comparison to UK, US and Germany (US$)
Table 5-2: Annual Cost of Utility for Conducting Phase I Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-3: Annual Cost of Staff for Conducting Phase II Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-4: Annual Cost of Utility for Conducting Phase II Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-5: Annual Cost of Staff for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-6: Annual Cost of Utility for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-7: Annual Cost of Staff for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-8: Annual Cost of Utility for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
Table 8-1: Comparison of Factors Affecting Clinical Trials Market among Different Countries